Ignite Creation Date:
2025-12-24 @ 9:21 PM
Ignite Modification Date:
2026-02-07 @ 8:55 PM
Study NCT ID:
NCT05877404
Status:
TERMINATED
Last Update Posted:
2024-04-19
First Post:
2023-05-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
Sponsor:
Wake Forest University Health Sciences
Organization:
Study Overview
Official Title:
Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer
Status:
TERMINATED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This was a national survey of physicians. Per the protocol, they were only allowed to be contacted twice and they received less surveys back than anticipated.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In order to formulate strategies to improve adherence to best practice guidelines, as well as utilization of novel therapies, investigators must understand current practice patterns surrounding tumor genetic testing in endometrial cancer. The aim is to survey a representative sample of gynecologic oncologists who belong to the society of gynecologic oncology, via an email survey, to better understand current practices surrounding tumor genetic testing as well as determine if there have been any changes to practice since the publication of recent trials on the use of immune-checkpoint inhibitors in endometrial cancer.
Detailed Description:
Primary Objective: Proportion of physicians reporting the use of different tumor genetic testing strategies among newly diagnosed endometrial cancer patients.
Secondary Objectives:
* Explore the use of informed consent in tumor genetic testing in endometrial cancer
* Explore clinician confidence in utilizing tumor genetic testing to guide treatment decisions.
* Explore the impact of recent publications regarding immunotherapy on the use of tumor genetic testing in endometrial cancer.
Secondary Objectives:
* Explore the use of informed consent in tumor genetic testing in endometrial cancer
* Explore clinician confidence in utilizing tumor genetic testing to guide treatment decisions.
* Explore the impact of recent publications regarding immunotherapy on the use of tumor genetic testing in endometrial cancer.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| WFBCCC 99323 | OTHER | Wake Forest Baptist Comprehensive Cancer Center | View | |
| P30CA012197 | NIH | None | https://reporter.nih.gov/quic… | View |
| NCI-2023-05554 | OTHER | CTRP | View |